Trials / Completed
CompletedNCT01358266
Study Assessing Double-masked Uveitis Treatment
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 592 (actual)
- Sponsor
- Santen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-109 44 ug | Low dose |
| DRUG | DE-109 440 ug | Medium dose |
| DRUG | DE-109 880 ug | High dose |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2016-09-01
- Completion
- 2016-12-01
- First posted
- 2011-05-23
- Last updated
- 2019-07-16
- Results posted
- 2019-07-16
Locations
151 sites across 17 countries: United States, Argentina, Austria, Brazil, Chile, Colombia, France, Germany, India, Israel, Italy, Japan, Peru, Poland, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01358266. Inclusion in this directory is not an endorsement.